tiprankstipranks
Trending News
More News >
Cronos Australia Ltd. (AU:VIT)
ASX:VIT
Australian Market
Advertisement

Cronos Australia Ltd. (VIT) AI Stock Analysis

Compare
15 Followers

Top Page

AU:VIT

Cronos Australia Ltd.

(Sydney:VIT)

Rating:62Neutral
Price Target:
AU$0.00
▼(-100.00% Downside)
The overall stock score is driven by strong financial growth and technical indicators showing moderate bullish momentum. However, the valuation and absence of dividend yield could be of concern for some investors. The company's ability to manage costs and improve cash flow will be key for future performance.

Cronos Australia Ltd. (VIT) vs. iShares MSCI Australia ETF (EWA)

Cronos Australia Ltd. Business Overview & Revenue Model

Company DescriptionVitura Health Limited engages in the sale and distribution of medicinal cannabis products in Australia and Asia. Its brands include CanView, Burleigh Heads Cannabis, CDA Clinics, Cannadoc, and Adaya. The company was formerly known as Cronos Australia Limited and changed its name to Vitura Health Limited in February 2023. The company was incorporated in 2018 and is based in South Yarra, Australia.
How the Company Makes MoneyCronos Australia Ltd. generates revenue primarily through the sale of its medicinal cannabis products. The company's key revenue streams include the direct sale of cannabis oils, capsules, and other derivatives to medical practitioners and pharmacies. Additionally, Cronos Australia Ltd. may engage in strategic partnerships and collaborations with other pharmaceutical companies to expand its product offerings and market reach. These partnerships can enhance its distribution network and provide additional revenue through licensing agreements or joint ventures. Factors such as regulatory compliance, product quality, and market demand significantly influence the company's earnings.

Cronos Australia Ltd. Financial Statement Overview

Summary
Cronos Australia Ltd. shows strong revenue growth and a healthy balance sheet, but recent declines in profit margins and cash flow generation indicate potential challenges.
Income Statement
65
Positive
Cronos Australia Ltd. has shown significant revenue growth over the years, particularly from 2021 to 2022, indicating strong market demand for its products. The Gross Profit Margin has been improving, suggesting better cost management. However, Net Profit Margin has recently decreased, pointing to increased operational costs or pricing pressures. The EBIT and EBITDA margins have weakened compared to previous years, indicating potential operational inefficiencies.
Balance Sheet
70
Positive
The company maintains a healthy equity position with an improving equity ratio, indicating financial stability. The Debt-to-Equity ratio is manageable, showing conservative leverage practices. Return on Equity has declined recently, reflecting on the reduced net income. Overall, the balance sheet remains strong with sufficient equity backing its operations.
Cash Flow
60
Neutral
Free Cash Flow Growth Rate has been negative, signaling potential challenges in generating free cash flow. However, Operating Cash Flow remains strong relative to net income, suggesting operational efficiency. The Free Cash Flow to Net Income Ratio has declined, indicating less cash being converted into income, which could impact future liquidity if trends continue.
BreakdownJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue123.87M117.34M66.99M1.69M123.85K
Gross Profit34.22M25.96M25.43M872.93K116.79K
EBITDA7.08M20.85M10.87M-486.62K-3.74M
Net Income3.51M13.81M6.05M-4.05M-3.94M
Balance Sheet
Total Assets71.28M46.90M42.87M12.69M16.23M
Cash, Cash Equivalents and Short-Term Investments11.35M18.85M16.08M9.47M14.69M
Total Debt11.02M1.28M5.06M2.36M2.21M
Total Liabilities32.84M11.99M16.79M3.47M2.73M
Stockholders Equity38.78M34.98M26.10M9.30M13.44M
Cash Flow
Free Cash Flow6.21M8.78M13.13M1.01M-5.16M
Operating Cash Flow7.00M9.71M13.50M1.07M-4.89M
Investing Cash Flow-13.20M-837.72K2.00M-160.69K-515.91K
Financing Cash Flow-1.30M-6.10M-1.50M-262.03K19.93M

Cronos Australia Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.07
Price Trends
50DMA
0.06
Positive
100DMA
0.07
Positive
200DMA
0.08
Negative
Market Momentum
MACD
<0.01
Negative
RSI
60.42
Neutral
STOCH
54.55
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:VIT, the sentiment is Positive. The current price of 0.07 is above the 20-day moving average (MA) of 0.07, above the 50-day MA of 0.06, and below the 200-day MA of 0.08, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 60.42 is Neutral, neither overbought nor oversold. The STOCH value of 54.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:VIT.

Cronos Australia Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (65)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
65
Neutral
¥333.03B8.12-3.93%2.48%10.31%-20.38%
62
Neutral
AU$49.01M20.884.85%5.76%-79.76%
$2.40M-21.29%
$5.94M-164.01%
$4.72M
AU$35.06M10.184.10%
41
Neutral
AU$20.29M-218.38%-14.30%29.69%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:VIT
Cronos Australia Ltd.
0.07
-0.02
-22.22%
ELLXF
Elixinol Wellness
0.03
0.00
0.00%
CNGGF
Cann Group
0.03
<0.01
50.00%
HDRPF
Epsilon Healthcare Limited
AU:LGP
Little Green Pharma Ltd.
0.10
0.01
11.11%
AU:AGH
Althea Group Holdings Ltd.
0.02
0.00
0.00%

Cronos Australia Ltd. Corporate Events

Vitura Health Issues Unquoted Equity Securities
Aug 4, 2025

Vitura Health Limited has announced the issuance of unquoted equity securities, including 12,814,845 unquoted options and 6,593,145 performance rights, effective from August 1, 2025. This move is likely aimed at enhancing the company’s capital structure and providing incentives for performance, which could have implications for its market positioning and stakeholder interests.

The most recent analyst rating on (AU:VIT) stock is a Buy with a A$0.12 price target. To see the full list of analyst forecasts on Cronos Australia Ltd. stock, see the AU:VIT Stock Forecast page.

Vitura Health Limited Announces Cessation of Performance Rights
Jul 8, 2025

Vitura Health Limited has announced the cessation of 137,979 performance rights due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This announcement may impact the company’s capital structure and could affect stakeholder perceptions regarding the company’s ability to meet its performance targets.

The most recent analyst rating on (AU:VIT) stock is a Buy with a A$0.12 price target. To see the full list of analyst forecasts on Cronos Australia Ltd. stock, see the AU:VIT Stock Forecast page.

Vitura Health Expands with Acquisition of Heyday Medical Clinic
May 18, 2025

Vitura Health Limited, through its joint venture Flora Holdings Pty Ltd, has acquired the Heyday Medical Clinic, a respected medicinal cannabis clinic in Australia. This acquisition strengthens Flora’s clinical network, positioning it as a leader in holistic healthcare, and expands patient access to both face-to-face and telehealth consultations. The deal involves acquiring key assets of Heyday Medical, with Vitura contributing 50% of the acquisition cost. The transition will see Heyday’s clinical team continue under Flora, enhancing the joint venture’s capacity to deliver quality patient care.

The most recent analyst rating on (AU:VIT) stock is a Buy with a A$0.12 price target. To see the full list of analyst forecasts on Cronos Australia Ltd. stock, see the AU:VIT Stock Forecast page.

Vitura Health Reports Positive Q3 FY2025 Momentum
May 11, 2025

Vitura Health Limited reported positive business momentum in Q3 FY2025, aligning with its Strategic Reset goals. The company saw successive revenue and EBITDA growth, driven by the integration of Candor Medical and Releaf Group, expansion of its Canview platform, and operational efficiencies. Despite slightly missing its annual revenue growth target, Vitura anticipates meeting its EBITDA margin and OPEX efficiency goals, setting a strong foundation for FY2026.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 30, 2025